Use of cardiovascular and antidiabetic drugs during COVID19 epidemic in France
Langue
EN
Article de revue
Ce document a été publié dans
Fundamental & Clinical Pharmacology. 2022-06, vol. 36, n° S1, p. 94-95
Résumé en anglais
Introduction: In this pandemic period, patients usually treated for one or more chronic diseases have faced difficulties in accessing care, voluntarily or not. The aim was to describe the impact of the COVID-19 epidemic ...Lire la suite >
Introduction: In this pandemic period, patients usually treated for one or more chronic diseases have faced difficulties in accessing care, voluntarily or not. The aim was to describe the impact of the COVID-19 epidemic on the use of chronic drugs used for cardiovascular diseases and diabetes mellitus in France. Material and methods: We analyzed data from the French nationwide health insurance database (SNDS) for the 17/09/2018 to 20/09/2020 time period. Drugs of interest were antidiabetic and cardiovascular drugs. The number of patients with treatment dispensing, ongoing, interrupted, or initiated treatment were identified for each week. We performed time-series analysis to describe use of drugs during the study period. Unobserved components model method was applied to predict use of drugs and compare it to observed use after 01/03/2020. Results: During the study period, 3,231,618 patients were identified with at least one dispensing for antidiabetic drugs and 14,822,132 patients for cardiovascular drugs. The one-week period preceding the first national lockdown was marked by a sharp spike in the amount of dispensings. Over the lockdown period, levels and trends in dispensings decreased until the very end of lockdown. The estimated overall impact of the lockdown on dispensings appeared limited with a lack ranging around 1–3%. This limited impact did not appear to be accompanied by an increase in the weekly numbers of treatment disruptions during the lockdown period, but with a significant decrease in treatment initiations were observed for almost all drug classes. The increases in treatment disruptions appeared more pronounced with the expected as predicted over the post-lockdown period for statins, almost all antihypertensive drugs and all antidiabetic drugs. Discussion/Conclusion: We were able to observe the great disparity in the care provided during the beginning of the COVID-19 epidemic in France. The COVID-19-related treatment disruptions undoubtedly resulted in increased health risk due to poor or even absent management.< Réduire
Unités de recherche